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During the last decade, alphaviruses became widely used for expression of heterologous genetic information and development of recombinant
vaccines against a variety of human and animal pathogens. In this study, we compared a number of vectors based on the genome of Sindbis
(SINV) and Venezuelan equine encephalitis (VEEV) viruses for their ability to express the Rift Valley fever virus (RVFV) envelope glycoprotein
Gn and induce a protective immune response against RVFV infection. Our results suggest that (i) application of VEEV-based expression systems
appears to be advantageous, when compared to similar systems designed on the basis of the SINV genome. (ii) Alphavirus-specific E3 and E2
proteins and furin-specific cleavage sites can be used for engineering secreted forms of the proteins. (iii) Alphaviruses can be modified for
expression of the large fragments of heterologous proteins on the surface of chimeric, infectious viral particles. Thus, alphavirus-based expression
systems may have the potential for a broader application beyond their current use as replicons or double-subgenomic vectors.
© 2007 Elsevier Inc. All rights reserved.Keywords: Alphaviruses; Recombinant vaccines; Chimeric virusesIntroduction
The alphavirus genus in the Togaviridae family is a group of
important and widely distributed human and animal pathogens
(Griffin, 2001; Strauss and Strauss, 1994). Alphaviruses
efficiently replicate in vertebrate hosts, in which they cause
an acute infection characterized by high-titer viremia that is
required for transmission to mosquito vectors during the blood
meal. In mosquitoes, they induce a persistent, life-long infection
and accumulate to high titers in salivary glands for transmission
to new hosts (Weaver and Barrett, 2004).
Alphavirus virions contain icosahedral nucleocapsid sur-
rounded by a lipid envelope with imbedded glycoprotein spikes.
The genome is represented by a single-stranded RNA molecule
of positive polarity, of approximately 11.7 kb in length (Kinney
et al., 1989; Strauss et al., 1984; Takkinen, 1986). It mimics the⁎ Corresponding author. Fax: +1 409 772 5065.
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methylguanylate cap and a 3′ polyadenylate tail. The genome
RNA is translated into four nonstructural proteins (nsP1-4) that
form, together with cellular proteins, the enzyme complex (RC)
required for viral genome replication and transcription of the
subgenomic RNA. The latter RNA, synthesized from the
subgenomic promoter, codes for structural proteins comprising
viral particles.
Since the first infectious cDNA clone of the alphavirus
genome was designed (Rice et al., 1987), these viruses became
an attractive system for the delivery and expression of
heterologous genetic information (Bredenbeek et al., 1993;
Liljeström and Garoff, 1991; Pushko et al., 1997). Their
application is based on the fact that viral structural genes can be
replaced by the genes of interest, and these RNAs (replicons)
remain self-replicating and become capable of expressing the
heterologous genetic information. Alphavirus replicons can be
packaged to high titers into infectious viral particles using so-
called helper RNAs (Bredenbeek et al., 1993; Fayzulin et al.,
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et al., 2006), which encode the cis-acting elements required for
replication of helper genome and transcription of the sub-
genomic RNA, translated into the structural proteins. Helpers
do not encode the entire set of nsPs (Volkova et al., 2006) and
may encode no nsPs at all (Liljeström and Garoff, 1991), and
they can replicate only in the presence of replicons, which
supply the replicative enzymes. Thus, they utilize a replicative
machinery, produced in trans by the replicons, and synthesize
structural viral proteins that package replicons into infectious
viral particles to titers approaching 1010 inf.u/ml. Depending on
the design, the helper RNAs are either packaged or not
packaged into infectious virions (Fayzulin et al., 2005; Volkova
et al., 2006). At the next passage, packaged replicons infect the
cells and express heterologous protein(s), encoded by the
subgenomic RNA, but do not develop spreading infection
because of the inability to produce viral structural proteins. An
alternative strategy of alphavirus-dependent gene expression is
based on duplication of the subgenomic promoter in the viral
genome and using it for expression of an additional gene
(Frolov et al., 1993; Hahn et al., 1992). In this case, the RNA
genome encodes all of the nonstructural and structural proteins
required for virus replication and development of productive
infection and is capable of producing the heterologous protein
encoded by the RNA transcribed from an additional subge-
nomic promoter. These two main strategies are applied in
vaccine development and in the expression of genes of interest,
both in vivo and in vitro.
In this study, we were interested in testing the above-
described replicon expression system and developing additional
alphavirus-based systems for expression of heterologous
genetic information, induction of the protective immune
response against lethal infection caused by Rift Valley fever
virus (RVFV) and production of the recombinant viruses at a
large scale.
RVFV is a representative member of the Bunyaviridae
family (Shope et al., 1982). This virus is continuously
circulating in livestock-raising regions of Africa, and intensive
farming has resulted in the emergence of mosquito-borne
epidemics (Ksiazek et al., 1989). Death rates are very high for
domestic animals, and, in particular, the fatality rate for fetuses
in pregnant livestock can approach 100%, while for newborn
lambs it is close to 90%. RVFV is spreading to new geographic
areas, and the recent outbreaks include an extensive epidemics
in Egypt in 1977 (Arthur et al., 1993) and in sub-Saharan
Africa in 1997–1998, and spread across the Red Sea to Saudi
Arabia and Yemen. RVFV has the potential for use in
bioterrorism, and its projected effect on U.S. agricultural
interests would likely be akin to the economic disruption seen
in cases of foot-and-mouth disease virus (FAMDV). However,
unlike FAMDV, RVFV can be transmitted by many different
species of mosquitoes (Tesh, 1988) and thus might cause
outbreaks in the areas where large mosquito populations exist
close to farms. RVFV is also an important human pathogen; it
causes a self-limited febrile, influenza-like illness that, in ∼2–
10% cases, results in hemorrhagic fever, liver necrosis,
encephalitis and eye damage. Based on data from epidemics,the estimated fatality rate in humans is close to 1% (Meegan et
al., 1979a,b).
The RVFV genome contains three, single-stranded RNA
segments (L, M and S) (Ihara et al., 1984; Pettersson et al.,
1977). The M segment encodes the NSm and viral envelope
glycoproteins Gn and Gc that are translated from a single
mRNA complementary to the M segment (Collett et al., 1985).
The latter RNA appears to employ a traditional strategy of viral
RNA templates, in which it encodes polyprotein precursors for
two mature structural proteins that are co- and post-translation-
ally processed. The carboxy terminal parts of NSm and Gn
contain signal peptides that likely function in translocation of
the following Gn and Gc, respectively, into the ER followed by
transport into the Golgi compartment.
Virions of the Bunyaviridae members are formed mainly
intracellularly by budding into the Golgi vesicles. However,
RVFV was found to bud through the external cellular membrane
as well (Anderson and Smith, 1987), which indicates that
significant glycoprotein fraction can be present on the external
surface of the infected cells. Immunization of mice with
recombinant Gc and Gn glycoproteins of RVFV, expressed by
baculoviruses or by recombinant vaccinia virus, has been shown
to protect the animals from viral disease (Keegan and Collett,
1986; Schmaljohn et al., 1989). Moreover, there are two
important neutralizing and protective antigenic epitopes on the
Gn glycoprotein of RVFV, and they are conserved among virus
strains from all over Africa (Battles and Dalrymple, 1988).
We tested a number of expression systems designed on the
basis of Sindbis (SINV) and Venezuelan equine encephalitis
virus (VEEV) genomes, and a variety of expression strategies
for RVFV Gn protein. The accumulated data suggest that VEEV
replicons expressing RVFV glycoproteins and VEE virus with a
chimeric envelope elicit the most efficient immune response
against RVFV infection, and such strategies might be applicable
in expressing the antigens of other viruses, particularly of these
having intracellular budding.
Results
SINV replicons expressing RVFV Gn
The initial constructs aimed at expression of RVFV-specific
antigen were designed on the basis of the SINV genome (Fig.
1A). The advantage of using SINV-based vectors is in their high
safety record, efficient expression of heterologous proteins in
vitro and the possibility of passaging of packaged SINV
replicons at an escalating scale as a tri-component genome virus
(Fayzulin et al., 2005). The SINrep/NSm+Gn+Gc replicon
encoded the entire ORF of RVFV M segment (a.a. 1–1197)
(Fig. 1B); SINrep/NSm+G2 encoded a.a. 1–674 with the stop
codon engineered instead of the Gc-specific signal peptide;
SINrep/spGn encoded a.a. 131–674; and the latter included the
signal peptide of Gn and the entire sequence of this protein up to
the Gc signal peptide. SINrep/spGn(opt) encoded exactly the
same protein as did SINrep/spGn, but this was a synthetic gene,
in which the codon frequency was the same as in the most
efficiently translated human mRNAs (Haas et al., 1996).
Fig. 1. The expression cassettes designed for expression of RVFV-specific antigen from SINV and VEEV replicons. (A) The schematic representation of SINV and
VEEV replicons used in the study. The arrow indicates the position of the subgenomic promoter. (B) The hydrophobicity profile (Kyte–Doolitle) of the entire
polyprotein encoded by the M segment of RVFV genome, and the fragments cloned into the subgenomic RNA of SINV replicon. The positions of signal peptides and
transmembrane domains are indicated by black boxes. The spGn(opt) synthetic gene, encoding exactly the same protein as does spGn, is indicated in grey color. The
starting and the last a.a. of each cassette are indicated.
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peptide of Gn and the Gn itself having transmembrane and
cytosol domains deleted.
All of the replicons (Fig. 2A) were packaged into viral
particles using two helper RNAs encoding either capsid or the
glycoproteins that either packaged only replicon genomes
(Bredenbeek et al., 1993) or were capable of self-packaging
(Fayzulin et al., 2005). Electroporation of the replicons and the
latter helpers generated tri-component genome viruses, and
such viruses could be passaged in tissue culture at an escalating
scale (one of the representative results is shown in Fig. 2B).
The designed constructs were tested for the level of RVFV
antigen expression, its distribution in the cellular compartments
and accumulation on the cell surface. All of the SINV replicons
efficiently expressed Gn (Fig. 2C). The NSm-containingFig. 2. SINV-based replicons used in the study and analysis of the expression of th
representation of the replicons and the titers of the packaged replicons obtained aft
multiple reproducible experiments is presented. The spGn(opt) synthetic gene is indi
SINrep/spGn(opt) replicon genome and the genomes of capsid- and glycoprotein-codi
12 h post-infection, the FBS-containing medium was replaced by serum-free VP-SFM
of packaged replicons were determined as described in Materials and methods. (C) An
BHK-21 cells were infected with packaged replicons at an MOI of 20 inf.u/cells or RV
for 12 h. Equal amounts of cell lysates were analyzed by electrophoresis in SDS–10%
by mouse anti-RVFVantibodies and IRdye 800CW-labeled secondary antibodies. Ima
virus-specific proteins in the cells infected with RVFV. BHK-21 cells were infected
with mouse anti-RVFV antibodies and AlexaFluor 546-labeled goat anti-mouse sec
cells; panel b presents surface staining of a nonpermeabilized cell. Gn and Gc develo
specific proteins in the cells infected with packaged SINV replicons that express d
genome. Panels a and b present cells infected with SINrep/NSm+Gn+Gc replicon, pa
present cells infected with SINrep/spGn, replicon, panels g and h present cells infect
cells that were permeabilized with Triton X-100 prior to immunostaining. Panel
permeabilization. Images were acquired on a Zeiss LSM510 META confocal micro
Materials and methods.constructs produced higher levels of Gn than did similar
constructs having only the carboxy terminal NSm fragment,
representing a signal peptide required for translocation of the
Gn protein into the endoplasmic reticulum. However, we
increased the level of signal peptide-containing Gn expression
by almost 4-fold by using a codon-optimized version of the
protein, instead of its natural, RVFV M segment-derived gene
(Fig. 2C).
Next, the expression of Gn was further analyzed by staining
the cells infected with RVFV MP12 and the packaged replicons
with RVFV-specific antibodies. Prior to antibody treatment,
cells were either fixed with 1% formaldehyde and permeabi-
lized with Triton X-100 (to monitor the intracellular distribution
of Gn) or only fixed (to evaluate the presence of Gn on the cell
surface). In the BHK-21 cells infected with attenuated MP12e RVFV-specific glycoproteins by the designed constructs. (A) The schematic
er co-transfection of the replicon and helper RNAs into BHK-21 cells. One of
cated in grey color. (B) Replication of the tri-component genome virus, having a
ng helpers, in BHK-21 cells. Cells were infected at an MOI of 8 inf.u/cell, and, at
medium. Samples of medium were taken at the indicated time points and titers
alysis of RVFV-specific protein expression in cells infected with SINV replicons.
FVMP12 at an MOI of 2.5 PFU/cell and incubated in complete medium at 37 °C
polyacrylamide gel, followed by Western blotting. Membranes were processed
ges were acquired on an Odyssey Infrared Imager (LI-COR). (D) Distribution of
with RVFV MP12 at an MOI of 50 PFU/cell and, at 13 h post-infection, stained
ondary antibodies. Panel a presents staining of the Triton X-100-permeabilized
p well-distinguishable patches on the cell surface. (E) Distribution of the RVFV-
ifferent fragments of the polyprotein encoded by the M segment of the RVFV
nels c and d present cells infected with SINrep/NSm+Gn replicon, panels e and f
ed with SINrep/spGn(secr) replicon. Panels a, c, e and g represent images of the
s b, d, f and h present images of the cells stained with antibodies without
scope using a 63× 1.4NA oil immersion planapochromal lens, as described in
215R. Gorchakov et al. / Virology 366 (2007) 212–225
216 R. Gorchakov et al. / Virology 366 (2007) 212–225strain of RVFV, the virus-specific glycoproteins accumulated in
the Golgi compartment, and a significant fraction was
transported to the cell surface (Fig. 2D). The detection of
antigen throughout the cytoplasm and in the nucleus was, most
likely, due to N and NSs distribution, because both proteins
were recognized by the used mouse antiserum on Western
blotting (data not shown).
Fig. 2E presents the results of the analysis of the Gn
distribution in the BHK-21 cells infected by different replicons.
The Gn, having a transmembrane domain and expressed by
SINrep/NSm+Gn+Gc, SINrep/NSm+Gn and SINrep/spGn,
accumulated in the Golgi compartment (panels a, c and e), but
was also readily detected on the cell surface (panels b, d and f),
where it formed discrete subdomains reminiscent of lipid rafts.
The size and distribution of these Gn-containing patches
differed for cassettes expressing Gn only and Gn+Gc. The
latter two proteins were distributed on the cellular membrane in
a manner similar to that found in RVFV MP12-infected cells:
Gn+Gc formed larger antigen-containing areas (compare Fig.
2D, panel b, with Fig. 2E, panel b). The Gn protein expressed by
SINrep/spGn(secr), having the signal peptide, but lacking the
transmembrane domain, was also efficiently expressed in BHK-
21 cells (Fig. 2E, panel g). However, in contrast to the
transmembrane domain-containing versions, it did not accumu-
late in the Golgi compartment but was distributed throughout
the cell, most likely in the ER. This truncated protein was not
detected at the cell surface (Fig. 2E, panel h), and it was not
secreted from the cell (data not shown). The replacement of the
RVFV-specific signal peptide by an SINV-derived E3 protein
that functions as a signal peptide for SINV E2 did not noticeably
improve the secretion, and the Gn was not detected in the media
either by immunoprecipitation or Western blotting (data not
shown).
The Gn-encoding, packaged SINV replicons were tested for
their ability to induce a protective immune response in mice. We
were interested in identifying a construct that could protect mice
with an efficiency comparable to that of live attenuated strain
RVFV MP12, which is one of the presently available vaccine
candidates. Therefore, mice were immunized once s.c. with
0.5–1×107 inf.u of packaged replicons and 105 PFU of MP12.
After 28 days they were challenged i.p. with 105 PFU of RVFV
ZH501. All of the MP12-immunized animals survived the
ZH501 infection without any sign of the disease; however, none
of the packaged SINV replicons protected mice in the challenge
experiments. In later experiments, some of the mice were
challenged s.c., as described in Materials and methods, and
were not protected against the disease as well. The PRNT80
titers detected in the immunized animals were always below
1:40. The extended survival time (data not shown) suggested
that repeated vaccinations could probably increase the effi-
ciency of protection. However, this is likely not an efficient
means of increasing the immune response.
Application of VEEV-based replicons for RVFV Gn expression
Based on our experience and published data (Perri et al.,
2003), VEEV replicons are more immunogenic than are similarSINV constructs. They have a number of advantages that
include the capability to more efficiently replicate in mice, large
animals, primates and humans (Johnston and Peters, 1996).
VEEV-based replicons can be also packaged to high titers using
defective helpers and efficiently passaged in tissue culture as a
virus with a tri-component genome (Volkova et al., 2006). Their
passaging in tissue culture at an escalating scale is achieved by
using VEEV-specific helpers that strongly differ from those
designed for SINV replicons. In order to package not only a
replicon, but also itself, VEEV helper RNAs have to express at
least nsP1-3 in cis. Thus, to compare VEEV- with SINV-based
replicons as expression systems in possible vaccine applica-
tions, we designed VEErep/spGn cassette, expressing RVFV
Gn, and used two different, VEEV-specific helper systems (Fig.
3A) for its packaging into infectious viral particles. This
particular expression cassette was utilized because the Gn is
known to contain neutralizing and protective epitopes (Battles
and Dalrymple, 1988), and expression of non-codon-optimized
Gn interfered less efficiently with VEEV replicon packaging
(data not shown). Helper RNAs encoded either nsP1-3 (H123/C
and H123/Gl helpers), or all of the VEEV nonstructural proteins
nsP1-4 (H1234/C and H1234/Gl helpers), in which nsP2
contained an attenuating P773→S mutation that had a strong
negative effect on RNA and virus replication (Volkova et al.,
2006). All of these packaging systems required a supply of the
replicative enzymes in trans by the VEEV replicons for
efficient helper RNA replication and production of the structural
proteins. In our previous studies, both pairs of helpers packaged
not only replicons, but also their own RNAs, and thus VEEV
replicon and two helper RNAs could be efficiently passaged in
the form of a tri-component genome virus (Volkova et al.,
2006).
VEEV replicon expressing RVFV spGn was packaged into
viral particles (Fig. 3A) that were used for analysis of protein
expression and immunization of mice. VEErep/spGn
expressed Gn noticeably more efficiently than did SINrep/
spGn (Fig. 3B), and the protein was localized not only in the
ER and Golgi compartment (Fig. 3C, panel a) but was also
present in high concentrations on the external membrane (Fig.
3C, panel b). Its distribution was similar to that found in the
cells infected with the SINrep/spGn replicon (compare Fig.
2E, panel f, with Fig. 3C, panel b). In mice, one
immunization with packaged VEErep/spGn did not induce
neutralizing antibodies to titers higher than those detected in
mice immunized with similar SINV-based replicons (data not
shown). The PRNT80 titers were always lower than 1:80.
However, even one immunization efficiently protected
animals against an ensuing infection with RVFV ZH501, a
finding consistent with the idea that VEEV replicons are more
immunogenic and hence more appropriate for development of
recombinant vaccines. However, the negative feature of the
VEErep/spGn replicon was in the strong effect of expressed
Gn on the assembly and/or release of the VEEV particles. In
contrast to our success with SINV replicons in terms of their
passaging in tissue culture, we were incapable of passaging
the Gn-expressing VEErep in cell culture, regardless of the
helpers used. Even after electroporation, the titers of the
Fig. 3. VEEV replicon and helpers used in the animal studies. (A) The schematic representation of the RVFV Gn-expressing VEEV replicon and two pairs of helpers
encoding VEEV capsid and glycoproteins. Representative titers, obtained in one of multiple, reproducible experiments, are indicated. (B) Analysis of RVFVGn
expression in cells infected with SINrep/spGn and VEErep/spGn replicons. BHK-21 cells were infected with packaged replicons at an MOI of 20 inf.u/cells and
incubated in complete medium at 37 °C for 12 h. Equal amounts of cell lysates were analyzed by SDS–10% polyacrylamide gel electrophoresis, followed by Western
blotting. Membranes were processed by mouse anti-RVFVantibodies and IRdye 800CW-labeled secondary antibodies. Images were acquired on an Odyssey Infrared
Imager (LI-COR). (C) Distribution of RVFV Gn in the cells infected with packaged VEErep/spGn replicon. BHK-21 cells were infected with the packaged replicon at
an MOI of 50 inf.u/cell and, at 12 h post-infection, stained with mouse anti-RVFV antibodies and AlexaFluor 546 goat anti-mouse secondary antibodies. Panel a
presents staining of the Triton X-100-permeabilized cells; panel b presents cell stained with antibodies without permeabilization. Images were acquired on a Zeiss
LSM510META confocal microscope using a 63× 1.4NA oil immersion planapochromal lens, as described in Materials and methods. (C) Survival of mice immunized
with 5×106 inf.u of packaged VEErep/spGn replicon and challenged in 42 days with 5×103 PFU s.c. of RVFV ZH501. The control group was injected with PBS and
challenged with the same dose of RVFV.
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with replicons expressing other heterologous genes (data not
shown). Thus, the possible problem with the large-scale
production of packaged Gn-encoding VEEV replicons should
be considered in the future studies.
Expression of RVFV Gn in VEEV structural polyprotein
The above-described experiments suggested a need for
additional approaches to enable the expression of RVFV
antigens by alphaviruses and the induction of protective
immune response against RVFV infection. The rationale was
to develop Gn expression systems that would be capable ofproducing secreted forms of Gn, either presented on the surface
of alphavirus particles or secreted from the cells as an
individual protein.
First, we attempted to express a secreted form of RVFV Gn
as a part of the alphavirus structural polyprotein. The Gn-coding
sequence, containing the signal peptide and the transmembrane
domain, was cloned between the VEEV capsid- and E3-coding
genes (Fig. 4). The FAMDV-derived 2A protease was fused
with the Gn cytosol domain to promote the processing of Gn
and following E3. VEEV capsid was expected to drive the
cleavage of capsid/Gn fusion by its intrinsic protease activity.
The recombinant virus was viable and capable of replicating to
titers higher than 108 PFU/ml. However, it demonstrated a
218 R. Gorchakov et al. / Virology 366 (2007) 212–225detectable level of instability and evolution to a large plaque
phenotype. Sequencing of the structural genes of the randomly
selected, plaque-purified variants revealed extended deletions
of the carboxy terminal fragment in the Gn-coding sequence.
These variants retained 109, 112 and 188 amino terminal and
very few carboxy terminal amino acids of Gn and the 2A
protease gene (Fig. 4). Their common feature was a deletion of
the transmembrane domain in the Gn, suggesting a negative
effect of this sequence on recombinant virus replication.
However, these mutants indicated that the selected expression
approach might be feasible. Therefore, we designed a set of
expression cassettes encoding RVFV Gn that lacked the
transmembrane domain (Figs. 5A and B). In the VEEV/C/
spGn(opt)/td−, this protein was expected to use its own, the
NSm-derived signal peptide for translocation into the ER, and
VEEV/Gn318(opt)/fur and VEEV/Gn239(opt)/fur were
designed in such a manner as to use VEEV E3 for the same
function. In the latter constructs, the VEEV-specific furin
cleavage sites were generated upstream and downstream from
the Gn sequence to promote processing of the polyprotein and
secretion of the recombinant Gn. All three viruses were viable
(Fig. 5B), and two of them, VEEV/C/spGn(opt)/td− and VEEV/
Gn239(opt)/fur, were stable during successive passages. Fig. 5C
presents a pattern of protein synthesis in the cell infected by
VEEV/C/spGn(opt)/td− and harvested after different passages
on BHK-21 cells.
All three Gn proteins, Gn340, Gn318 and Gn239, were
secreted, and only the VEEV E1 and E2 were detected in the
viral particles (Fig. 5D), indicating the complete processing of
the VEEV structural proteins. However, if the secreted Gn318
and Gn239 corresponded to the expected sizes, the secreted
Gn340 had a significantly higher molecular weight than
expected, and, on the gel, this protein was seen to run slower
than did the Gn340-2A fusion, detected in the protein samples
isolated from the infected cells (compare Fig. 5C with Fig. 5D).
That difference was unlikely to result from additional
glycosylation because the Gn318 and the Gn340 had the same
predicted glycosylation sites. The most plausible explanation
for finding the protein of higher molecular weight was that, inFig. 4. The schematic representation of the VEEV genomes encoding the RVFV G
mutants. The positions of found in-frame deletions in the Gn a.a. sequence are indicits secreted form, the Gn remained fused with E3. Thus, the
completely processed Gn340-2A appeared to be retained in the
cells, and the Gn340-2A-E3 was, most likely, secreted. To test
this hypothesis, we designed a VEEV/C/spGn(opt)E3/td−
recombinant virus that differed from the above-described
VEEV/C/spGn(opt)/td− by the lack of FAMDV 2A protease.
This deletion made processing of Gn340/E3 fusion an
impossible event. This virus was also viable, stable, formed
large plaques and secreted Gn to the media during replication.
The molecular weight of the latter protein was almost the same
as that of secreted during VEEV/C/spGn/td− replication (Fig.
5E); however, a change in protein size, caused by 2A sequence
deletion, was readily detectable (Figs. 5D and E). The RVFV-
specific antibodies precipitated from the media proteins of
lower molecular weight than that of the major secreted proteins
(Figs. 5D and E). The exact nature of these products remains
unclear. They could be either a result of partial degradation of
the secreted Gn or incomplete glycosylation of Gn proteins.
These additional polypeptides were not further investigated in
this study.
Thus, fusion with E3 at least during the early stages of
protein transport was required for protein secretion. Taken
together, the data indicated that (i) alphavirus-derived E3 can
function in the transport of heterologous proteins from infected
cells; (ii) alphavirus spike glycoproteins are required for this
efficient transport as well; (iii) both carboxy and amino terminal
fusions of E3 can be utilized for transport of heterologous
polypeptides; and (iv) the furin-specific cleavage sites can
efficiently function in a heterologous context to produce the
proteins of interest in an unfused form.
Alphaviruses with chimeric envelopes
The previously published data strongly indicated that
alphavirus E2 glycoprotein could tolerate insertion of extended
heterologous protein sequences into the very amino terminal
fragment without a deleterious effect on virus replication
(Klimstra et al., 2005; London et al., 1992). To test the
possibility of designing infectious alphaviruses having chimericn protein in the structural polyprotein and the genomes of the selected deletion
ated.
Fig. 5. The expression cassettes designed for expression of secreted forms of RVFV Gn and analysis of the Gn expression. (A) The hydrophobicity profile (Kyte–
Doolitle) of the Gn protein. Fragments cloned into the VEEV structural polyprotein are indicated by black lines. (B) The schematic representation of the recombinant
VEEV genomes, containing the insertions of the Gn-encoding sequences in the subgenomic RNA. The numbers correspond to the positions of the first and the last a.a.
of the insertion in the polyprotein encoded by the RVFV M segment. The triangles indicate positions of engineered and natural furin-specific cleavage sites. Indicated
viral titers and plaque size were derived from one of multiple, highly reproducible experiments. (C) Analysis of the stability of VEEV/C/spGn(opt)td− during serial
passaging in tissue culture. Virus was passaged three times in BHK-21 by infecting the monolayer of BHK-21 cells in 100-mm dishes with 100 μl of the stock
harvested at the previous passage. For analysis of protein expression, BHK-21 cells were infected with harvested viruses and VEEV TC-83 at an MOI of 20 PFU/cell.
At 16 h post-infection, cells were labeled with [35S]methionine, as described in Materials and methods, and equal aliquots of proteins were analyzed by electrophoresis
in SDS–10% polyacrylamide gels. The positions of VEEV-specific proteins and Gn-2A are indicated. Asterisks indicate the positions of incompletely processed
products. (D and E) Analysis of proteins expressed by the recombinant viruses and secreted to the medium. Metabolic labeling of the proteins was performed as
described in Materials and methods. Viral particles (V) were pelleted by ultracentrifugation and the RVFV Gn proteins were isolated by immunoprecipitation. Samples
were analyzed by electrophoresis in SDS–10% polyacrylamide gels, followed by autoradiography. The positions of proteins and molecular weight markers are
indicated. The molecular weights of the expressed Gn protein fragments and its fusion forms, predicted based on the a.a. sequence, are indicated in the brackets. Gn239
and Gn318 contain one potential glucosylation site, Gn340-2A-E3 and Gn340-E3 have two potential sites.
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developed a variety of VEEV genome-based constructs with
Gn-specific insertions in the E2 gene (Fig. 6A). The selection of
these sequences was based on an analysis of Gn's hydro-
phobicity profile and the available data about the antigenic
structure of the protein (London et al., 1992). These Gn-specific
fragments were cloned into the amino terminus of E2 in such a
manner as to save a furin-specific cleavage site downstream
from E3, and no cleavage sites for proteolytic processing
between the Gn sequence and E2 were created. The recombi-
nant, viable viruses were rescued from the cDNA, and it was notsurprising that their replication efficiency decreased with the
increase in the length of a Gn-specific insertion (Fig. 6B). The
peptides' insertions were readily detectable in the pulse-labeling
experiments (Fig. 6C), and, in the pulse-chase experiments, we
found a processed Gn/E2 (lacking E3), but no E2 (Fig. 6D). The
latter protein was present only in the samples prepared from cells
infected with VEEV/Gn239(opt)/fur and VEEV/Gn318(opt)/fur
viruses (described in the previous section) encoding the same Gn
fragments separated from E2 by engineered furin-specific
cleavage sites (see Figs. 5B and 6D). Even the longest peptide,
Gn318, was efficiently transported as Gn/E2 chimeric protein to
Fig. 6. The expression cassettes designed for expression of RVFV Gn in viral particles and analysis of the protein expression. (A) The hydrophobicity profile (Kyte–
Doolitle) of the Gn protein. Fragments cloned into VEEV structural polyprotein are indicated by black lines. (B) The schematic representation of the recombinant
VEEV genomes containing the insertions of the Gn-encoding sequences in the subgenomic RNA. The numbers correspond to the positions of the first and the last a.a.
of the insertion in the polyprotein encoded by the RVFV M segment. The triangles indicate positions of engineered furin-specific cleavage sites. VEEV-specific
sequences are indicated in grey color. Indicated viral titers and plaque size were derived from multiple experiments. (C and D) The results of metabolic labeling of the
proteins expressed by recombinant viruses. The pulse labeling (C) and pulse-chase labeling (D) with [35S]methionine, followed by SDS–10% polyacrylamide gel
electrophoresis, were performed at 16 h post-infection as described in Materials and methods. Final processing products of furin protease are indicated by
asterisks. (E) Distribution of Gn-E2 fusion protein in the VEEV/Gn318(opt)-infected cells. Panel a represents images of the cells that were permeabilized with Triton
X-100 prior to immunostaining with RVFV-specific antibodies. Panel b presents images of the cells stained with the same antibodies without permeabilization. Images
were acquired on a Zeiss LSM510 META confocal microscope using a 63× 1.4NA oil immersion planapochromal lens, as described in Materials and methods.
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infectious viral particles (data not shown) that had E2 replaced
by Gn/E2 fusion.
Taken together, these data indicated that the application of
alphaviruses for expression of RVFV Gn is not limited by using
them in a replicon form that encodes heterologous proteins under
control of the additional subgenomic promoter. The structural
protein-specific signal sequences and the structural proteins
themselves can be used for secretion of heterologous proteins in
form of infectious viral particles having chimeric envelope.
Protection experiments
Some of the designed recombinant viruses were tested in
mice for their ability to induce a protective immune response
against RVFV infection. The results of these experiments are
presented in Figs. 7A and B. Mice were immunized once or
twice with the recombinant viruses that expressed either a
secreted form of RVFV Gn (VEEV/Gn239(opt)/fur and VEEV/
C/spGn(opt)/td−) or a fusion of E2 with the Gn fragment [VEE/
SINV/Gn318 and VEEV/Gn318(opt)]. After immunization,Fig. 7. Survival of mice immunized with the indicated recombinant viruses after
s.c. challenge with 5×103 PFU of RVFV ZH501. Mice were immunized either
once (A) or twice (B) and challenged as described in Materials and methods.mice were challenged s.c. with 5×103 PFU of RVFV ZH501 in
42 days (or 21 days, if two immunizations were used). The
results of these experiments (Figs. 7A and B) suggested that all
of the constructs induced at least partial protection against the
challenging virus, and two immunizations were detectably
more efficient than a single one. However, the most important
result was that replicating viruses with chimeric envelope,
having VEEVor SINV E2 fused in the amino terminus with the
318-a.a.-long fragment of RVFV Gn, protected mice more
efficiently. One immunization with VEEV/Gn318(opt) pro-
tected against the dose of ZH501 used, and mice developed no
clinical signs of the disease.
Discussion
Within the last several years, alphavirus expression
systems have become widely used for the delivery and
expression of heterologous genetic information both in vitro
and in vivo. SINV and VEEV expression systems are mainly
based on the application of so-called replicons, self-
replicating RNAs, in which the structural genes, encoded
by the subgenomic RNAs, are replaced by the genes of
interest. These recombinant virus-specific RNAs can be
packaged into infectious viral particles by the structural
proteins, supplied in trans by replication-competent helpers
or other expression systems, and infect the cells as do
normal, unmodified alphaviruses. However, replicons are not
the only means of heterologous gene expression. Alpha-
viruses have also developed unique mechanisms of structural
protein transport and processing. For example, their E3
proteins are highly unusual signal peptides that do not
remain in the cell-specific membranes after translocation of
the following E2 into the ER but are rather secreted from the
cells in free form or as a component of mature viral particles
(Mayne et al., 1984; Strauss and Strauss, 1994). Therefore,
in the present study, in addition to evaluating the antigen
presentation capacity of the alphavirus replicons, we made an
attempt to use VEEV- and SINV-specific intracellular protein
transport machinery for delivery of the RVFV envelope
glycoprotein Gn outside of the cells for its presentation to
the immune system.
Both VEEV- and SINV-based replicons were capable of
efficient Gn expression, and surprisingly high concentration of
this protein accumulated not only in the ER and trans-Golgi
compartment but was present at the cell surface at a high
concentration, regardless of its expression in natural NSm+Gn
+Gc cassette or as a single protein having its signal peptide.
However, after one immunization, only VEEV-specific,
packaged replicons were capable of inducing the immune
response that protected mice against the RVFV ZH501
challenge. This can be explained by the higher levels of
VEEV RNA replication in vivo and/or the stronger resistance
of this virus replication to the autocrine action of IFN-α/β
(White et al., 2001). However, VEEV replicons appear to be
imperfect in vaccine applications against RVFV infection
because of the strong interference of Gn with VEEV replicon
packaging. This makes technically difficult passaging of
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of infectious viral particles.
The deletion of the Gn transmembrane domain did not cause
the latter protein to be secreted from the cells, and it no longer
accumulated in the trans-Golgi compartment, but was mostly
present in the ER. The replacement of a Gn signal peptide with
E3 did not cause improved secretion of this protein from the
cells. In order to be secreted that fusion protein required other
VEEV or SINV structural proteins to be involved in transport.
Consequently, the truncated Gn was transported outside of the
cell when it was fused with the carboxy or amino terminus of E3
and synthesized as an E2-containing polyprotein. Thus, both E3
and E2 proteins were required for efficient intracellular transport
and, ultimately, for secretion. This was particularly noticeable in
the study of Gn340 synthesis and transport in VEEV/C/spGn
(opt)/td−-infected cells, in which the Gn340-2A remained in the
cells, and the uncleavedGn340-2A-E3 (that remained fusedwith
E2 until the processing with furin protease at the very late stages
of transport) was secreted (Fig. 5). Thus, the use of alphavirus-
specific E3 and E2, and engineering of furin-specific cleavage
sites in the carboxy and/or amino termini of the expressed
protein provides an efficient means for secretion of the proteins
that have a strong potential for the intracellular accumulation. In
this study, we succeeded in secretion of large Gn fragments both
as free proteins and on the surface of the alphavirus particles.
The secreted forms of Gn, expressed by VEEV/Gn239(opt)/fur,
VEEV/C/spGn(opt)/td− and VEEV/C/spGn(opt)E3/td− (Fig.
5B), demonstrated poor immunogenicity (Fig. 7 and data not
shown). However, the Gn fragments, expressed as Gn/E2
fusions on the cell surface and in the envelope of viral particles,
produced by VEE/SINV/Gn318 or VEEV/Gn318(opt) (Figs. 6B
and E) during virus replication in vivo, induced a protective
immune response against RVFV ZH501 even after a single
immunization (Fig. 7). It should be noted that after one
immunization, the titers of neutralizing antibodies (PRNT80)
did not exceed 1:60 (data not shown). Previous studies of
the immune response induced by the nonsecreted VEEV
glycoproteins expressed on the cell surface by the
recombinant vaccinia virus suggested that protection against
very high doses of VEEV TRD, those approaching 108
LD50, could be achieved even when the neutralizing
antibodies titers were at very low levels, similar to those
detected in the present experiments (Kinney et al., 1988a;
Kinney et al., 1988b; Sviatchenko et al., 1993). In the above-
described studies, we could not distinguish between the
possibilities of whether the RVFV-specific antigen expressed
on the surface of the cells during virus replication (Fig. 6E) was
sufficient for eliciting an immune response, or the Gn in the viral
particles made an additional contribution to protection. How-
ever, the accumulated data about the high level of immunogeni-
city of HBs (Fomsgaard et al., 1998; Woo et al., 2006) or HBc
(Fehr et al., 1998; Mihailova et al., 2006) particles, expressing
additional antigens, suggest the latter possibility as a possible
event.
Taken together, the results of this study indicate that (i)
application of VEEV-based replicons and other VEEV-based
expression systems for induction of protective immune responseagainst RVFV infection appears to be advantageous, when
compared to similar systems designed on the basis of the SINV
genome. (ii) Alphavirus-specific E3 protein, viral structural
protein E2 and furin-specific cleavage sites can be used for
engineering secreted forms of the proteins that are normally
transported to the cell surface and released from the cells very
inefficiently. However, as we demonstrated for RVFV Gn, the
secretion of these proteins does not necessarily lead to the
induction of an efficient immune response. (iii) Alphaviruses
can be modified for expression of the large fragments of
heterologous proteins as fusions with E2 glycoproteins, and such
fusions can be used in the context of replicating virus for
presentation of the protein both on the cell surface and on the
surface of the chimeric, infectious viral particles. Thus,
alphavirus-based expression systems may have the potential
for a broader application beyond their current use as replicons or
double-subgenomic vectors.
Materials and methods
Cell cultures and viruses
BHK-21 cells were kindly provided by Dr. Sondra Schle-
singer (Washington University, St. Louis, MO). Cells were
maintained at 37 °C in alpha minimum essential medium
(αMEM) supplemented with 10% fetal bovine serum (FBS) and
vitamins. VEEV TC-83 was derived from an infectious cDNA
clone of the viral genome. The attenuated strain of RVFVMP12
(Morrill et al., 1997) was obtained from Dr. Clarence Peters
(UTMB).
Plasmid constructs
The plasmid encoding the entire ORF of RVFV ZH501 M
segment was provided by Dr. Connie S. Schmaljohn
(USAMRIID). pSINrep/NSm+Gn+Gc encoded SINV repli-
con (Bredenbeek et al., 1993), cloned under the control of
SP6 RNA polymerase promoter and containing the entire
ORF of the M segment (a.a. 1–1197) under the control of the
subgenomic promoter. pSINrep/NSm+Gn encoded the entire
NSm and Gn (a.a. 1–674) of the polyprotein, while pSINrep/
spGn encoded the Gn only, including the amino terminal
signal peptide. pSINrep/spGn(secr) contained in the subge-
nomic RNA the ORF that covers a.a. 131–581 of Gn.
pSINrep/spGn(opt) encoded the same RVFV-specific protein
sequence as did pSINrep/spGn, but the nucleotide sequence
was designed based on the codon frequency of human genes
that demonstrate a high translation efficiency (Haas et al.,
1996). The spGn(opt) ORF was synthesized from the
oligonucleotides using the PCR-based technique. A schematic
representation of the Gn fragments and replicons is shown in
Figs. 1B and 2A, respectively. pVEErep/spGn contained
VEEV TC-83-based replicon (Petrakova et al., 2005) having
the described above spGn cassette cloned under the control of
the subgenomic promoter. Helpers used for SINV replicon
packaging are described elsewhere (Fayzulin et al., 2005), and
VEEV helpers encoding nsP1-3, H123/C and H123/Gl were
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VEEV-specific helpers H1234/C and H1234/Gl had a very
similar design, in which they encoded the same subgenomic
RNAs as did H123/C and H123/Gl. However, in their
genomes, all of the nonstructural genes were present and the
nsP2 contained an attenuating mutation P773 to S that strongly
reduced their cytopathogenicity (Petrakova et al., 2005). The
schematic representation of the VEEV replicon and helper
genomes is shown in Fig. 3A. pVEEV/C/spGn(opt) contained
a promoter of SP6 RNA polymerase, followed by a cDNA
copy of the VEEV TC-83 genome, in which the spGn(opt)
(fused with FAMDV 2A protease) cassette was cloned in
frame between a capsid-coding sequence and E3. In addition,
9 nucleotides, coding 3 amino terminal amino acids of VEEV
E3, were left upstream of the signal peptide-coding sequence
of codon-optimized Gn and an extra proline-coding codon
was added to the 5′ terminus of the E3 gene. These two
modifications were required for polyprotein processing by
capsid and 2A proteases. The schematic representation of
recombinant viral genome is shown in Fig. 4. pVEEV/C/spGn
(opt)/td− had a design similar to that of pVEEV/C/spGn(opt),
but in the Gn-coding fragment, a sequence encoding a
carboxy terminal part of the protein, including the transmem-
brane domain, was deleted, and the ectodomain fragment of
Gn was fused with 2A protease (Fig. 5). In pVEEV/C/spGn
(opt)E3/td−, a 2A protease sequence was deleted, and the Gn
ectodomain-coding gene (a.a. 132–471) was fused with E3
(Fig. 5B). pVEEV/Gn318(opt)/fur and pVEEV/Gn239(opt)/
fur contained VEEV TC-83 genomes, in which the insertions
encoding 318 and 239 a.a. of Gn, respectively, were made
between E3 and E2. The Gn-specific sequences did not
contain both the signal peptide- and transmembrane domain-
coding fragments. The furin-specific cleavage sites were
engineered between VEEV E3 and Gn, and between Gn and
VEEV E2. The schematic representation of viral genomes is
presented in Fig. 5B. pVEEV/Gn318(opt), VEEV/Gn239
(opt), pVEEV/Gn98, pVEEV/Gn73 and pVEEV/Gn27 con-
tained VEEV TC-83 genomes having the insertions of codon-
optimized or wt RVFV Gn-coding sequence of different
length, fused with the VEEV E2 gene (for details, see Fig.
6B). The furin-specific cleavage site sequence was engineered
in the junction between VEEV E3- and RVFV Gn-coding
genes. pSINV/Gn318 and pVEE/SINV/Gn318 had a design
similar to that of pVEEV/Gn318(opt). Insertions of the Gn
fragment (having a wt, but not codon-optimized sequence)
encoding 318 a.a. of the protein were cloned between E3 and
E2 genes into an infectious cDNA clone of the SINV genome
(SINV/Gn318) or chimeric VEEV genome, in which the
VEEV structural genes were replaced by those of SINV
(Garmashova et al., 2007).
All of the described replicons and viruses encoding the
RVFV-specific sequences were engineered using standard
PCR-based cloning techniques. All of the PCR products were
sequenced to avoid any accumulation of spontaneous
mutations in the recombinant DNAs. The details of the
cloning procedures and sequences of the plasmids can be
provided upon request.RNA transcriptions
Plasmids were purified by centrifugation in CsCl gradients.
Before the transcription reaction, SINV genome-based plasmids
were linearized using the XhoI restriction site located down-
stream of the poly(A) sequence. Plasmids containing recombi-
nant VEEV genomes were linearized by NotI or MluI. RNAs
were synthesized by SP6RNApolymerase in the presence of cap
analog by previously described conditions (Rice et al., 1987).
The yield and integrity of the transcripts were analyzed by gel
electrophoresis under nondenaturing conditions. Transcription
reactions were used for electroporation without additional
purification.
RNA transfections
BHK-21 cells were electroporated by using previously
described conditions (Liljeström et al., 1991). Packaged
replicons were harvested at 19–30 h post-transfection. Titers
were determined by infecting BHK-21 cells with serial
dilutions of the stocks. After 16 h incubation at 30 °C in a
CO2 incubator, cells were fixed with 1% formaldehyde,
permeabilized with Triton X-100 and stained with RVFV-
specific antibodies, obtained from Dr. Robert Tesh (UTMB),
and secondary antibodies labeled with AlexaFluor 546. Cell
samples electroporated with the in vitro-synthesized viral
genomes were tested in the infectious center as previously
described (Gorchakov et al., 2005) to assess the accumulation
of deletion mutants having higher rates of replication and
forming larger plaques. The residual electroporated cells were
seeded into 100-mm dishes, and viruses were harvested after
development of profound CPE. Virus titers were determined
using a standard plaque assay on BHK-21 cells (Lemm et al.,
1990).
Analysis of protein synthesis
BHK-21 cells were seeded into six-well Costar plates at a
concentration of 5×105 cells/well. After 4 h incubation at 37 °C
in 5% CO2 they were infected at an MOI of 20 PFU/cell or 20
infectious units (inf.u)/cell by viruses or packaged replicons,
respectively, in 200 μl of αMEM supplemented with 1% FBS at
37 °C for 1 h with shaking. The medium was then replaced by a
corresponding complete medium, and incubation continued at
37 °C. At 16 h post-infection, the cells were washed three times
with phosphate-buffered saline (PBS) and then incubated for
30 min at 37 °C in 0.8 ml of DMEM lacking methionine,
supplemented with 0.1% FBS and 20 μCi/ml of [35S]
methionine. After this incubation, cells were scraped into the
media, pelleted by centrifugation and dissolved in 300 μl of
standard protein gel loading buffer. Equal amounts of proteins
were loaded onto sodium dodecyl sulfate–10% polyacrylamide
gels. After electrophoresis, gels were dried and autoradio-
graphed. In the pulse-chase protein labeling experiments, the
[35S]methionine-containing media were replaced by complete
media, and incubation was continued for 2 h in the CO2
incubator at 37 °C. Then cells were collected, and proteins were
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polyacrylamide gels.
Immunoprecipitation experiments
BHK-21 cells were seeded at a concentration of 5×105 cells/
35-mm dish. After 4 h incubation at 37 °C, the subconfluent
monolayers that formed were infected with different viruses at
an MOI of 20 PFU/cell for 1 h, and incubated in complete
medium in a CO2 incubator at 37 °C. At 20 h post-infection, the
cells were washed three times with PBS and then incubated for
6 h at 37 °C in 0.8 ml of DMEM lacking methionine,
supplemented with 0.1% FBS and 20 μCi/ml of [35S]
methionine. By that time, cells did not demonstrate profound
CPE, characterized by destruction of the membrane and release
of the cytoplasmic content. Harvested media were additionally
centrifugated at 13,500 rpm for 5 min at room temperature and
used for analysis of both VEEV particles and secreted RVFV-
specific proteins. Virions were pelleted by centrifugation
through the cushion of 20% sucrose in an MLS-50 rotor in
Beckman Optima MAX ultracentrifuge at 48,000 rpm for 1 h at
4 °C, then dissolved in standard protein gel loading buffer and
analyzed on sodium dodecyl sulfate–10% polyacrylamide gels.
The supernatants, harvested after ultracentrifugation, were
incubated with mouse anti-RVFV antibodies and protein A,
linked to magnetic beads (Miltenyi Biotec). The 35S-labeled
RVFV Gn was eluted from the μColumns (Miltenyi Biotec) by
SDS-containing protein gel loading buffer and analyzed on
sodium dodecyl sulfate–10% polyacrylamide gels.
Microscopy
For microscopy, BHK-21 cells were seeded on the glass
chamber slides (Nunc) and infected with recombinant viruses or
packaged replicons at an MOI of 50 PFU or inf.u per cell. Then
glass chambers were incubated in a CO2 incubator at 37 °C for
12 h. Next, they were fixed in 1% formaldehyde in PBS and
either directly stained with RVFV-specific mouse antibodies
and goat anti-mouse, AlexaFluor 546-labeled secondary anti-
bodies (for surface staining). Alternatively, the same staining
was done after their permeabilization with 0.5% Triton X-100
(for staining of the intracellular proteins). Further analysis was
performed on a Zeiss LSM510 META confocal microscope
using a 63× 1.4NA oil immersion planapochromal lens. For
three-dimensional analysis of surface staining, the image stacks
were further processed using Huygens Essential v2.7 deconvo-
lution software (Scientific Volume Imaging) and 3D rendering
software Imaris v 4.2 (Bitplane AG).
Animals
Balb/c mice, 6-week-old females, were purchased from
Harlan and housed for at least 7 days in a specific pathogen-free
environment until they were immunized. Immunization studies
were carried out under ABSL-2 conditions, and all of challenge
studies were conducted under ABSL-4 conditions in the Robert
E. Shope, BSL4 Laboratory, UTMB. All of the animal studieswere approved by the Institutional Animal Care and Use
Committee and carried out according to NIH guidelines.
Immunization and challenge with virulent RVFV
Mice were inoculated on day 0 subcutaneously (s.c.) into the
medial thigh with tested viruses or packaged replicons at a dose
of 5×106 PFU or inf.u, respectively, in a total volume of 100 μl
of PBS. Some animals received an additional booster on day 21,
which was performed in the same way as the initial
immunization. Mice were challenged either s.c. (5×103 PFU)
or i.p. (1×105 PFU) with virulent RVFV ZH501.
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